Fed Circuit reinstates $235m verdict against Teva

06-10-2020

Sarah Morgan

Fed Circuit reinstates $235m verdict against Teva

JHVEphoto / Shutterstock.com

In a victory for GlaxoSmithKline (GSK), the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg (Carvedilol).


Federal Circuit, Teva, GlaxoSmithKline, GSK, patent infringement, generic, Coreg, induced infringement, skinny labels

LSIPR